Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levornidazole disodium phosphate is a **water-soluble intravenous formulation** of levornidazole, the L-isomer phosphate salt derivative of ornidazole and a member of the nitroimidazole class of anti-infective agents[7][6][9]. It is used primarily for the **treatment and prevention of infections caused by anaerobic bacteria**, including intra-abdominal, pelvic, oral, surgical, brain infections, as well as sepsis and bacteremia[7][3][1]. Levornidazole acts as a DNA-modulating agent, disrupting DNA synthesis in susceptible microorganisms[9]. Compared to ornidazole and L-ornidazole, its phosphate disodium form offers markedly improved water solubility, less vascular irritation, and minimal central nervous system suppression[7][6]. It is administered intravenously, especially when oral nitroimidazoles are unsuitable or less effective[1][7]. First approved in China in May 2021[9], it is developed and manufactured primarily by Chinese pharmaceutical companies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levornidazole disodium phosphate.